SMAD7 and renal cell carcinoma: Previous studies have shown that miR182‐5p contributes to renal cell carcinoma proliferation by activating the AKT/FOXO3a signaling pathway10 and that miR‐452‐5p promotes the proliferation of RCC by modulating SMAD4/SMAD7 signaling.11